Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has shared an update.
Chimeric Therapeutics Limited responded to an ASX query regarding the ADVENT-AML clinical trial results. The company disclosed that no dose-limiting toxicities were observed, and CORE-NK cells persisted in patients’ blood. Notably, 57% of high-risk frontline subjects showed clinical responses, with two new complete responses in AML. This information, although not initially disclosed, is considered to have a potential material impact on the company’s securities when combined with additional new data.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited is a biotechnology company focused on developing innovative therapies for cancer treatment. The company is involved in clinical trials, such as the ADVENT-AML trial, which utilizes its CORE-NK technology, primarily funded by MD Anderson Cancer Center.
Technical Sentiment Signal: Sell
Current Market Cap: A$10.93M
For detailed information about CHM stock, go to TipRanks’ Stock Analysis page.